This article is part of the supplement: 52nd Annual Meeting of the Society for Research into Hydrocephalus and Spina Bifida .

Oral presentation

Blood to cerebrospinal fluid barrier in spontaneous hypertension and ventricular dilation

Agustin Castañeyra-Perdomo^1,2 , Ibrahim González-Marrero², Paloma Fernández-Rodríguez², Juan M Gonzalez-Toledo¹, Leandro Castañeyra-Ruiz², Maria E Segui², Agustin Castañeyra-Ruiz², Hector de Paz-Carmona¹, Isabel Hernandez-Garde¹ and Emilia M Carmona-Calero^1,2

¹  Departamento de Anatomía, Facultad de Medicina, Universidad de La Laguna, Tenerife, Spain

²  Departamento de Biotecnología, Instituto de Investigación y Ciencias de Puerto del Rosario, Fuerteventura, Spain

author email corresponding author email

from 52nd Annual Meeting of the Society for Research into Hydrocephalus and Spina Bifida
Providence, RI, USA. 11–14 June 2008

Cerebrospinal Fluid Research 2009, 6(Suppl 1):S6doi:10.1186/1743-8454-6-S1-S6

Published:	3 February 2009

First paragraph (this article has no abstract)

Arterial hypertension produces ventricular dilation, CSF protein composition variations as well as alterations in the circumventricular organ and choroid plexus (CP). Cerebrospinal fluid (CSF) has an important relationship with the blood and the brain, and encephalic pathology could alter the connections between the blood, brain and CSF, and consequently the protein composition of the CSF. Furthermore, certain proteins could be used as markers such as transthyretin and S-100β, which are extravasated when central nervous system (CNS) barriers are breached. The S-100β is primarily synthesized in the brain by the astrocytes and is released into the blood when the blood brain barrier (BBB) is disrupted. Transthyretin is a protein primarily located in the brain in choroid plexus (CP), subcommissural organ (SCO) and, as soluble monomer, in the CSF, where it has a positive gradient for extravasation in peripheral blood, when the blood to CSF barrier (BCB) is altered. The aim of the present work is to analyze the CNS barriers in the arterial hypertension using antibodies against S-100β, transthyretin monomer (TTRm), TA-p73 and Reissner fibre (AFRU).